Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/40396
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Valgimigli, M | - |
dc.contributor.author | Smits, PC | - |
dc.contributor.author | Frigoli, E | - |
dc.contributor.author | Bongiovanni, D | - |
dc.contributor.author | Tijssen, J | - |
dc.contributor.author | Hovasse, T | - |
dc.contributor.author | Mafragi, A | - |
dc.contributor.author | Ruifrok, WT | - |
dc.contributor.author | Karageorgiev, D | - |
dc.contributor.author | Aminian, A | - |
dc.contributor.author | Garducci, S | - |
dc.contributor.author | Merkely, B | - |
dc.contributor.author | Routledge, H | - |
dc.contributor.author | Ando, K | - |
dc.contributor.author | Fernandez, JFD | - |
dc.contributor.author | Cuisset, T | - |
dc.contributor.author | Malik, FTN | - |
dc.contributor.author | Halabi, M | - |
dc.contributor.author | Belle, L | - |
dc.contributor.author | Din, J | - |
dc.contributor.author | Beygui, F | - |
dc.contributor.author | Abhyankar, A | - |
dc.contributor.author | Reczuch, K | - |
dc.contributor.author | Pedrazzini, G | - |
dc.contributor.author | Heg, D | - |
dc.contributor.author | VRANCKX, Pascal | - |
dc.date.accessioned | 2023-06-14T09:26:59Z | - |
dc.date.available | 2023-06-14T09:26:59Z | - |
dc.date.issued | 2022 | - |
dc.date.submitted | 2023-06-07T15:45:30Z | - |
dc.identifier.citation | EUROPEAN HEART JOURNAL, 43 (33) , p. 3100 -3114 | - |
dc.identifier.uri | http://hdl.handle.net/1942/40396 | - |
dc.description.abstract | Aim To assess the effects of 1- or >= 3-month dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents for complex percutaneous coronary intervention (PCI) and/or acute coronary syndrome (ACS). Methods and results In the MASTER DAPT trial, 3383 patients underwent non-complex (abbreviated DAPT, n = 1707; standard DAPT, n = 1676) and 1196 complex (abbreviated DAPT, n = 588; standard DAPT, n = 608) PCI. Co-primary outcomes at 335 days were net adverse clinical events [NACE; composite of all-cause death, myocardial infarction, stroke, and bleeding academic research consortium (BARC) 3 or 5 bleeding events]; major adverse cardiac or cerebral events (MACCE; all-cause death, myocardial infarction, and stroke); and Types 2, 3, or 5 BARC bleeding. Net adverse clinical events and MACCE did not differ with abbreviated vs. standard DAPT among patients with complex [hazard ratio (HR): 1.03, 95% confidence interval (CI): 0.69-1.52, and HR: 1.24, 95% CI: 0.79-1.92, respectively] and non-complex PCI (HR: 0.90, 95% CI: 0.71-1.15, and HR: 0.91, 95% CI: 0.69-1.21; P-interaction = 0.60 and 0.26, respectively). BARC 2, 3, or 5 was reduced with abbreviated DAPT in patients with and without complex PCI (HR: 0.64; 95% CI: 0.42-0.98, and HR: 0.70; 95% CI: 0.55-0.89; P-interaction = 0.72). Among the 2816 patients with complex PCI and/or ACS, NACE and MACCE did not differ and BARC 2, 3, or 5 was lower with abbreviated DAPT. Conclusion In HBR patients free from recurrent ischaemic events at 1 month, DAPT discontinuation was associated with similar NACE and MACCE and lower bleeding rates compared with standard DAPT, regardless of PCI or patient complexity. | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.subject.other | Percutaneous coronary intervention | - |
dc.subject.other | High bleeding risk | - |
dc.subject.other | Dual antiplatelet therapy | - |
dc.subject.other | Complex intervention | - |
dc.title | Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 3114 | - |
dc.identifier.issue | 33 | - |
dc.identifier.spage | 3100 | - |
dc.identifier.volume | 43 | - |
local.bibliographicCitation.jcat | A1 | - |
local.publisher.place | GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1093/eurheartj/ehac284 | - |
dc.identifier.isi | 000815258900001 | - |
local.provider.type | Web of Science | - |
local.uhasselt.international | yes | - |
item.validation | ecoom 2023 | - |
item.fulltext | With Fulltext | - |
item.accessRights | Open Access | - |
item.fullcitation | Valgimigli, M; Smits, PC; Frigoli, E; Bongiovanni, D; Tijssen, J; Hovasse, T; Mafragi, A; Ruifrok, WT; Karageorgiev, D; Aminian, A; Garducci, S; Merkely, B; Routledge, H; Ando, K; Fernandez, JFD; Cuisset, T; Malik, FTN; Halabi, M; Belle, L; Din, J; Beygui, F; Abhyankar, A; Reczuch, K; Pedrazzini, G; Heg, D & VRANCKX, Pascal (2022) Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. In: EUROPEAN HEART JOURNAL, 43 (33) , p. 3100 -3114. | - |
item.contributor | Valgimigli, M | - |
item.contributor | Smits, PC | - |
item.contributor | Frigoli, E | - |
item.contributor | Bongiovanni, D | - |
item.contributor | Tijssen, J | - |
item.contributor | Hovasse, T | - |
item.contributor | Mafragi, A | - |
item.contributor | Ruifrok, WT | - |
item.contributor | Karageorgiev, D | - |
item.contributor | Aminian, A | - |
item.contributor | Garducci, S | - |
item.contributor | Merkely, B | - |
item.contributor | Routledge, H | - |
item.contributor | Ando, K | - |
item.contributor | Fernandez, JFD | - |
item.contributor | Cuisset, T | - |
item.contributor | Malik, FTN | - |
item.contributor | Halabi, M | - |
item.contributor | Belle, L | - |
item.contributor | Din, J | - |
item.contributor | Beygui, F | - |
item.contributor | Abhyankar, A | - |
item.contributor | Reczuch, K | - |
item.contributor | Pedrazzini, G | - |
item.contributor | Heg, D | - |
item.contributor | VRANCKX, Pascal | - |
crisitem.journal.issn | 0195-668X | - |
crisitem.journal.eissn | 1522-9645 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ehac284.pdf | Published version | 1.26 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.